Brief Title
Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
Official Title
A Prospective, Multicenter Study of the Cordis Endovascular QUANTUM LP™ Stent Graft System for the Treatment of Abdominal Aortic Aneurysms (AAA)-FORTRON
Brief Summary
The objective of this clinical study is to assess the safety and effectiveness of the Cordis Endovascular Quantum LP™ Stent Graft System.
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
To compare the aneurysm-related one-year mortality rates of the stent graft patients to open surgery patients. The purpose of having an aneurysm surgically or endovascularly repaired is to prevent death from AAA.
Secondary Outcome
To evaluate the occurrence of severe device-related adverse events as they relate to the cause of aneurysm exclusion failures (i.e., Type I and III endoleaks, significant AAA growth, or AAA rupture).
Condition
Abdominal Aortic Aneurysm
Intervention
QUANTUM LP™ STENT GRAFT SYSTEM
Study Arms / Comparison Groups
1
Description: QUANTUM LP™ STENT GRAFT SYSTEM
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
300
Start Date
November 2001
Completion Date
April 2009
Primary Completion Date
December 2004
Eligibility Criteria
Inclusion Criteria (Surgical Patients): 1. Non-emergent surgical candidate (aneurysm has not ruptured) 2. Patients 21 years of age or older 3. Male or infertile Female 4. Aneurysm >/=4.5 cm in diameter, or 5. Aneurysm >/= twice the normal aortic diameter directly above the aneurysm, or 6. Aneurysm >/= 4.0 cm in diameter and rapidly growing (0.5 cm in 6 months), or 7. Saccular aneurysm > 3.0 cm Inclusion Criteria (Stent Graft Patients) 1. Patient meets all inclusion criteria for surgical candidate 2. Aneurysm starts >/= 10 mm below the most distal main renal artery and the diameter of aorta within that aortic neck segment is not variable 3. Diameter of aortic fixation zone (neck) >/= 22mm and = 30 mm 4. Supra renal aortic diameter = 34 mm 5. The required device coverage length >/= 13 cm extending from most distal main renal artery ostium to the distal anchoring site within the common iliac artery (or external iliac artery if planned occlusion of internal iliac artery) 6. Aortic neck angulation < 60° as estimated from CT scan images or angiogram 7. Iliac artery attachment zone diameter = 20 mm 8. Iliac arteries with a length of >/= 10 mm of non-aneurysmal vessel located at the iliac graft attachment sites 9. Iliac arteries with adequate peripheral access to accommodate a 22 Fr catheter delivery system 10. Aortic bifurcation > 18 mm in diameter 11. Creatinine level < 2.5 mg/dl Exclusion Criteria (Surgical and Stent Graft Patients): 1. Weight > 350 lbs. (159 Kg) 2. Mycotic, ruptured or traumatic aneurysm 3. Life expectancy < 2 years 4. MI, cerebral vascular accident or transient ischemic attack (TIA) within 6 months 5. Expected occlusion or the need for re-implantation of significant mesenteric or renal arteries originating from the AAA Exclusion Criteria (Stent Graft Patients only) 1. Aneurysm is symptomatic or tender 2. Creatinine > 2.5 mg/dl or patient on dialysis 3. Thrombus in proximal and distal attachment area covering greater than 50% of the endoluminal surface
Gender
All
Ages
21 Years - N/A
Accepts Healthy Volunteers
No
Contacts
H. Wayne Hutman, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00233688
Organization ID
P01-4601
Study Sponsor
Cordis Corporation
Study Sponsor
H. Wayne Hutman, MD, Study Director, Cordis Corporation
Verification Date
April 2009